What are the precautions for Roflumilast-DALIRESP?

In clinical studies of Roflumilast Tablets (Roflumilast)-DALIRESP for the treatment of chronic obstructive pulmonary disease (COPD; COPD), warnings and precautions such as the treatment of acute bronchospasm, psychiatric events (including suicide), weight loss, and drug interactions have emerged. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. Treatment of acute bronchospasm: Roflumilast tablets are not bronchodilators and should not be used to relieve acute bronchospasm.

2. Psychiatric events, including suicide: Treatment with roflumilast tablets will increase psychiatric adverse reactions. The most commonly reported psychiatric adverse reactions were insomnia, anxiety, and depression, which were reported at higher rates in patients taking roflumilast 500 mcg daily. Instances of suicidal ideation and behavior, including outright suicide, have been observed in clinical trials. In the postmarketing setting, cases of suicidal ideation and behavior, including outright suicide, have been observed in patients with and without a history of depression.

Prescribers should carefully weigh the risks and benefits of roflumilast before using roflumilast in patients with a history of depression and/or suicidal thoughts or behaviors. Patients, their caregivers, and families should be informed to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts, or other mood changes and to contact their health care provider if such changes occur. If such an event occurs, the prescriber should carefully evaluate the risks and benefits of continued treatment with roflumilast.

3. Weight loss: Weight loss is a common adverse reaction in clinical trials of roflumilast tablets. According to reports, 7.5% of patients taking 500mcg of roflumilast tablets once a day experienced weight loss; yes20% experienced moderate weight loss Loss (defined as 5-10% of body weight) , 7% of patients experienced severe (>10% of body weight) weight loss. At follow-up after treatment discontinuation, most patients who lost weight regained some of the weight they had lost while receiving roflumilast. Patients receiving roflumilast should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, the weight loss should be evaluated and discontinuation of roflumilast should be considered.

4. Drug interactions: The metabolism of roflumilast is mainly carried out by cytochromeP450 enzymes, including CYP3A4 and CYP1A2. When using strong cytochrome P450 enzyme inducers (such as rifampicin, carbamazepine, phenytoin), the plasma concentration of roflumilast may be reduced, thus affecting its therapeutic effect. Therefore, it is recommended to avoid the combined use of these drugs with roflumilasttablets.

In summary, roflumilast tabletsIt has certain efficacy in the treatment ofCOPD, but it is also accompanied by a variety of potential adverse reactions, including mental problems and weight changes. Clinicians need to fully evaluate the patient's specific situation when prescribing, especially patients with a history of mental illness, and must use it with caution. At the same time, necessary education should be provided to patients to ensure that they understand possible side effects so that related problems can be discovered and dealt with in a timely manner.

Reference materials:https://www.medicines.org.uk/emc/product/5650/pil#gref